Riskpilot← Back to searchSign inGet full accessHudkræftklinikken.dk ApS
APSActiveCVR 38219960Dampfærgevej 3Medical specialists activities · NACE 8622Est. 20164 employeeswww.hudkræftklinikken.dk
Revenue 2025
DKK 1,9M
-8% vs 2024
EBITDA margin
2.2%
-87% vs 2024
Equity ratio
42.3%
Financial strength
Net profit 2025
DKK -210K
-2370% vs 2024
| Revenue | DKK 1,9M | -8% |
| EBITDA | DKK 42K | -87% |
| Net profit | DKK -210K | -2370% |
| Total assets | DKK 1,8M | -23% |
| Equity | DKK 757K | -53% |
| Employees | 4 | — |
Legal name
Hudkræftklinikken.dk ApS
CVR number
38219960
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
20. november 2016
Share capital
DKK 118.889
Employees
4 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren alene, af formanden for bestyrelsen sammen med et medlem af bestyrelsen eller af den samlede bestyrelse
Company purpose
Virksomhedens formål er drift af speciallægevirksomhed
Address
Dampfærgevej 3
Email
bb@hudkraeftklinikken.dk
Website
www.hudkræftklinikken.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.520 | 1.640 | 2.116 | 1.731 | 1.767 | 1.292 | 1.290 | 2.055 | 1.898 |
| Staff expenses | -554 | -928 | -1.161 | -884 | -932 | -1.474 | -1.228 | -1.722 | -1.856 |
| EBITDA | 281 | 199 | -612 | 847 | 836 | -197 | 63 | 333 | 42 |
| Depreciation & amort. | -118 | -118 | -198 | -201 | -208 | -215 | -254 | -254 | -254 |
| EBIT | 163 | 81 | -810 | 646 | 627 | -412 | -191 | 80 | -211 |
| Net financials | -63 | -23 | -9 | -479 | -27 | -51 | -75 | -64 | -55 |
| Profit before tax | 99 | 58 | -819 | 167 | 600 | -462 | -266 | 16 | -266 |
| Tax | -0 | -0 | -0 | -0 | 43 | -99 | -56 | 6 | -56 |
| Net profit | 99 | 58 | -819 | 167 | 557 | -363 | -211 | 9 | -210 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.310 | 3.375 | 2.771 | 2.485 | 2.997 | 2.305 | 2.739 | 2.315 | 1.792 |
| Equity | 249 | 3.307 | 2.221 | 2.404 | 2.562 | 1.169 | 1.588 | 1.597 | 757 |
| Long-term debt | 1.018 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.043 | 68 | 551 | 81 | 393 | 1.136 | 1.150 | 717 | 1.035 |
| Total debt | 2.061 | 68 | 551 | 81 | 393 | 1.136 | 1.150 | 717 | 1.035 |
EBITDA margin
2.2%
This company
15.8%
Market median
-86% vs market
20172025
Equity ratio
42.3%
This company
38.2%
Market median
+11% vs market
20172025
Return on equity
-27.8%
This company
18.4%
Market median
-251% vs market
20172025
Net profit margin
-11.1%
This company
8.1%
Market median
-237% vs market
20172025
Asset turnover
1.06×
This company
1.12×
Market median
+5% vs market
20172025
Debt / equity
1.37×
This company
0.62×
Market median
-121% vs market
20172025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-11-20 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BB Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
M.Glud holding ApS | Company | 33.3% | 33.3% | 2016 |
Birch Bengtsen Invest ApS | Company | 33.3% | 33.3% | 2016 |
PHOENIX CAPITAL ApS | Company | 10.0% | 10.0% | 2023 |
Progressio Invest ApS | Company | 5.0% | 5.0% | 2025 |
Bjorktorpet Invest ApS | Company | 10.0% | 10.0% | 2018 |
Hudkræftklinikken.dk ApS | Company | 10.0% | 10.0% | 2022 |
Saroori Engelbrecht holding ApS | Company | 15.0% | 15.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Birch Bengtsen Invest ApS
Hudkræftklinikken.dk ApS Board members of Hudkræftklinikken.dk ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bolette Birch Bengtsen | Chief Executive Officer | 0 companies |
| Inanna Pia Weiss | Board of Directors | 0 companies |
| Martin Glud | Board of Directors | 0 companies |
| Kent Stevens Larsen | Board of Directors | 0 companies |
| Robert Birger Birch | Chairman | 0 companies |